Embolism material containing bleomycin as well as preparation method and application of embolism material

By using temperature-sensitive nanogel-loaded bleomycin materials in cerebral arteriovenous malformation interventional embolization, the problems of high recurrence rates and adverse reactions in the prior art are solved, and the effect of reducing the number of treatments and improving the durability of treatment is achieved. .

CN118903528AInactive Publication Date: 2024-11-08GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410962816.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure CN118903528A_ABST
    Figure CN118903528A_ABST
Patent Text Reader

Abstract

The invention discloses an embolism material containing bleomycin as well as a preparation method and application of the embolism material. The bleomycin-containing embolism material comprises a drug, a carrier and a developing agent, the drug is bleomycin, the carrier is pNIPAM-BMA nanogel, and the developing agent is iohexol. The invention also discloses a preparation method of the embolism material. The preparation method comprises the following steps: firstly, preparing pNIPAM-BMA nanogel through a precipitation polymerization method; then, the pNIPAM-BMA nanogel is mixed with a developing agent, and an IBI dispersion body is formed; and adding bleomycin into the IBI dispersion, and fully mixing to obtain the bleomycin-containing embolism material. The embolism material is applied to an embolism agent for treating cerebral arteriovenous malformation, and fibrosis of tissues around targeted blood vessels can be promoted by embolizing abnormal blood vessels through the bleomycin-containing embolism material disclosed by the invention, so that a long-term stable embolism effect is provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the fields of biomedical engineering and nanotechnology, and specifically relates to an embolic material containing bleomycin and a preparation method and application thereof. Background Art

[0002] Brain arteriovenous malformation (bAVM for short) is a congenital variation of local cerebral blood vessels. There is a lack of capillaries between the cerebral arteries and veins at the site of the lesion, resulting in direct communication between the arteries and veins, forming a short circuit between the arteries and veins, leading to a series of symptoms of cerebral hemodynamic disorders. This complex cerebrovascular disease is often clinically manifested as repeated intracranial hemorrhage, partial or systemic epileptic seizures, transient ischemic attacks, and progressive neurological dysfunction. It is also the second cause of spontaneous intracranial subarachnoid hemorrhage. Therefore, brain arteriovenous malformations seriously threaten the patient's quality of life and life expectancy. The goal of the treatment of brain arteriovenous malformations is to completely eliminate blood flow through abnormal blood vessels to eliminate the risk of bleeding. The treatment of brain arteriovenous malformations mainly relies on surgical resection and interventional embolization.

[0003] Cerebral arteriovenous malformations are usually accompanied by a high recurrence rate and require multiple interventional embolization treatments. The choice of vascular embolization materials in interventional embolization directly determines the effectiveness of the treatment. For vascular embolization materials, the following characteristics are usually required: 1. Good fluidity, easy to inject through the catheter, no sticking to the tube, no blocking of the tube; 2. Reasonable embolization strength and resistance to blood flow erosion; 3. Good visibility to guide the delivery of embolization materials to the correct target site; 4. Long-term controlled release of drugs.

[0004] There are still some shortcomings in the materials currently used for vascular embolization. For example, cerebral arteriovenous malformations require multiple interventional embolization treatments, and some embolic materials may cause adverse reactions to surrounding tissues.

[0005] Therefore, stable, non-toxic and harmless embolic materials are needed to improve the stability of embolism and reduce the number of interventional embolization treatments for cerebral arteriovenous malformations. Summary of the invention

[0006] The present invention aims at the above-mentioned problems, makes up for the deficiencies of the prior art, and provides an embolic material containing bleomycin. The material utilizes temperature-sensitive polymer pNIPAM-BMA nanogel to load bleomycin (BLM for short). The pNIPAM-BMA nanogel is converted into a gel state at body temperature, and can stably release BLM in the embolic area, promote targeted vascular fibrosis, thereby effectively blocking abnormal blood vessels, and reducing the number of interventional embolic treatments for cerebral arteriovenous malformations.

[0007] The specific technical solutions are as follows:

[0008] An embolic material containing bleomycin comprises a drug, a carrier and a developer; the drug is bleomycin, the carrier is pNIPAM-BMA nanogel, and the developer is iohexol.

[0009] Preferably, the concentration of bleomycin is 30 g / L, and the volume ratio of the pNIPAM-BMA nanogel to iohexol is 1:1.

[0010] Another object of the present invention is to provide a method for preparing an embolic material containing bleomycin, comprising the following steps: first preparing a pNIPAM-BMA nanogel by precipitation polymerization; then mixing the pNIPAM-BMA nanogel with iohexol in a volume ratio of 1:1 to form an IBI dispersion; adding bleomycin to the IBI dispersion, wherein the concentration of the bleomycin is 30 g / L, and fully mixing the bleomycin to obtain an embolic material containing bleomycin.

[0011] Preferably, the specific steps of preparing pNIPAM-BMA nanogel by the precipitation polymerization method are as follows: 1.13 g of N-isopropylacrylamide, 108 ul of butyl methacrylate, 3.2 mg of N,N'-methylenebisacrylamide and 17 mg of sodium dodecyl sulfate are added to 100 ml of ultrapure water, mixed, heated to 70°C, stirred, and nitrogen gas was introduced for 1 hour; then 27 mg of potassium persulfate was added to initiate polymerization, and the reaction was maintained at 70°C for 4.5 hours to obtain an IB nanogel dispersion, which was dialyzed for 7 days to remove unreacted monomers and other small molecules to obtain a pNIPAM-BMA nanogel.

[0012] Another object of the present invention is to provide an application of an embolic material containing bleomycin, wherein the embolic material containing bleomycin is applied as an embolic agent for treating cerebral arteriovenous malformations.

[0013] The bleomycin-containing embolic material of the present invention is inserted into the cerebral arteriovenous malformation through an embolic agent to block abnormal blood vessels and promote fibrosis of surrounding tissues.

[0014] The sufficient mixing in the present invention refers to mixing by vortex oscillation for 5 minutes and magnetic stirring for 12 hours.

[0015] When used, after the embolic material of the present invention is inserted, the embolic material changes from a sol state to a gel state at body temperature to achieve the purpose of slowly releasing the drug bleomycin, promoting the fibrosis of the targeted blood vessels, and reducing the recurrence of bAVM.

[0016] Beneficial effects of the present invention:

[0017] The present invention produces a novel embolic material with temperature sensitivity and biocompatibility. The drug bleomycin carried in the material slowly releases its efficacy to promote fibrosis of the targeted blood vessels, thereby effectively blocking abnormal blood vessels and reducing the recurrence of bleeding symptoms. After the embolic material of the present invention is injected into the treatment area, it can achieve a transition from a sol state to a gel state at body temperature, thereby promoting the slow release of the drug. At the same time, the embolic material of the present invention can also significantly promote fibrosis through the TGF-β / Smad 3 signaling pathway, thereby providing a long-term and stable embolic effect.

[0018] Appendix Description

[0019] For clear comparison, pNIPAM-BMA nanogels were mixed with the developer iohexol to form an IBI dispersion, abbreviated as IBI; the embolic material containing bleomycin was abbreviated as IBI-BLM. In the figure, D7 represents the 7th day, D14 represents the 14th day, and D28 represents the 28th day.

[0020] Figure 1 This is the morphology characterization diagram of IBI-BLM.

[0021] Figure 2 The phase transition process of IBI and IBI-BLM at 25℃ and 37℃.

[0022] Figure 3 AFM image of the morphology of IBI at 25°C.

[0023] Figure 4 AFM image of the morphology of IBI at 37°C.

[0024] Figure 5 This is the shear viscosity diagram of IBI.

[0025] Figure 6 This is the shear viscosity diagram of IBI-BLM.

[0026] Figure 7 The graph shows the stable release of bleomycin from IBI-BLM in vitro.

[0027] Figure 8 Comparison of the surrounding tissue reactions after subcutaneous injection of IBI and IBI-BLM in mice.

[0028] Fig. 9 Comparison of the thickness of the fibrous capsule around the subcutaneous biomaterials in mice after injection of IBI and IBI-BLM, respectively.

[0029] Fig.10 This is a bar graph comparing the thickness of the fibrous capsule around the subcutaneous biomaterials in mice after injection of IBI and IBI-BLM, respectively.

[0030] Fig.11This is a comparison of the renal tissue structure shown in HE staining before and 14 days after embolization.

[0031] Fig.12 Microscope images and partial magnifications of RM Masson-stained histological sections at D7, D14, and D28 after IBI embolization. (Magnified is a partial magnification)

[0032] Fig.13 Microscope images and partial magnifications of RM Masson-stained histological sections at D7, D14, and D28 after IBI-BLM embolization. (Magnified is a partial magnification)

[0033] Fig.14 Comparison of the thickness of vascular wall fibrous tissue at D7, D14, and D28 after IBI and IBI-BLM embolization.

[0034] Fig.15 HE staining images of major pig organs (brain, liver, pancreas, lung, kidney, and heart).

[0035] Fig.16 Shows the protein expression of TGF-β, Smad 3, and P-Smad 3.

[0036] Fig.17 This is a bar chart comparing the protein expressions of TGF-β, Smad 3, and P-Smad 3.

[0037] Fig.18 This is the protein expression of CollagenⅠ, CollagenⅢ, CollagenⅣ, Laminin a-2, and Fibronectin.

[0038] Fig.19 This is a bar chart comparing the protein expressions of CollagenⅠ, CollagenⅢ, CollagenⅣ, Laminin a-2, and Fibronectin. DETAILED DESCRIPTION

[0039] In order to make the technical problems, technical solutions and beneficial effects solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific implementation methods. It should be understood that the specific implementation methods described herein are only used to explain the present invention and are not used to limit the present invention.

[0040] The carrier used in the examples was prepared according to the following steps:

[0041] 1.13 g of N-isopropylacrylamide (NIPAM), 108 ul of butyl methacrylate (BMA), 3.2 mg of N,N'-methylenebisacrylamide (BIS) and 17 mg of sodium dodecyl sulfate (SDS) were added to 100 ml of ultrapure water, mixed, heated to 70°C, stirred, and nitrogen was introduced for 1 hour; then 27 mg of potassium persulfate was quickly added to initiate polymerization, and the reaction was maintained at 70°C for 4.5 hours to obtain an IB nanogel dispersion, which was dialyzed for 7 days (cutoff molecular weight of 14000 Da) to remove unreacted monomers and other small molecules to obtain pNIPAM-BMA nanogel, which was stored in a room temperature desiccator.

[0042] Example 1

[0043] 25 ml of pNIPAM-BMA nanogel was mixed with 25 ml of iodohexanol to form an IBI dispersion.

[0044] 1.5 g of bleomycin was added to the IBI dispersion and mixed thoroughly to form an embolic material containing bleomycin with a concentration of 30 g / L, namely, IBI-BLM, which was stored at 4° C. for subsequent use.

[0045] Example 2

[0046] 50 ml of pNIPAM-BMA nanogel was mixed with 50 ml of iodohexanol to form an IBI dispersion, and 3 g of bleomycin was added to the IBI dispersion and mixed thoroughly to form an embolic material containing bleomycin with a concentration of 30 g / L, namely, IBI-BLM.

[0047] Example 3

[0048] 10 ml of pNIPAM-BMA nanogel was mixed with 10 ml of iodohexol to form an IBI dispersion, and 0.6 g of bleomycin was added to the IBI dispersion and mixed thoroughly to form an embolic material containing bleomycin with a concentration of 30 g / L, namely, IBI-BLM.

[0049] Characterization of IBI-BLM

[0050] The morphology of IBI-BLM was characterized by a transmission electron microscope (TEM, Tecnai G220, FEI Company, The Netherlands) at 200 kV. Figure 1 As shown, IBI-BLM has good uniformity and the morphology of IBI-BLM is spherical nanoparticles.

[0051] Figure 2The phase transition process of IBI and IBI-BLM at 25°C and 37°C is shown, indicating that IBI and IBI-BLM transform from sol state to gel state at 37°C.

[0052] like Figure 3 and Figure 4 By comparison, it can be seen that the height of IBI dried at 37℃ on mica ( Figure 4 ) compared to the height of IBI dried at 25℃ on mica ( Figure 3 ) decreased, indicating that IBI showed a contraction state at 37°C. This shows that IBI has a release effect, so the volume will decrease.

[0053] Shear viscosity of IBI and IBI-BLM

[0054] from Figure 5 and Figure 6 It can be seen that the viscosity of IBI and IBI-BLM is moderate, so when the IBI and IBI-BLM of the present invention are used in a catheter, the catheter wall will not become sticky and the catheter will not be blocked.

[0055] In vitro release behavior of IBI-BLM

[0056] Weigh 0.3 ml of IBI-BLM and place it in a dialysis bag (MwCO 8-14K). Seal the bag at 37°C and place it in 100 ml of release medium (DMSO). Place the bag in a 150 ml conical flask and place it on a shaker at 37°C at 250 rpm.

[0057] Release medium was taken at 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 48 h, 72 h, 96 h, 120 h and 144 h. After sampling, an equal volume of DMSO solution was added to keep the total volume constant. The sampled test solution was measured for absorbance at 295 nm using an ELISA reader (Epoch, Winooski, USA), and the percentage of bleomycin released was calculated and analyzed.

[0058] GraphPad Prism software was used for linear fitting to generate a standard curve of cumulative BLM release, i.e., the in vitro drug release curve of IBI-BLM at 37°C ( Figure 7 ). In the initial stage of release, burst release of BLM was observed, followed by sustained release, and release equilibrium was reached after about 12 hours. At 144 hours, the drug release amount reached 80%. It can be seen that at 37°C, the embolic material containing bleomycin of the present invention can release BLM for a long time.

[0059] In vivo release behavior of IBI and IBI-BLM mice

[0060] IBI and IBI-BLM were injected subcutaneously into BALB / c mice to evaluate the effects of nanogel maintenance and drug release in vivo.

[0061] Tissues near the nanogel reservoir were collected on days 7 (D7 group), 14 (D14 group), and 28 (D28 group) after administration for visual inspection and histological analysis.

[0062] like Figure 8 As shown, the integrity of the nanogels was maintained for more than 28 days, and the size of the residual gels slowly decreased with time. Figure 8 There was more surrounding fibrous tissue in the IBI-BLM group than in the IBI group.

[0063] Masson staining showed collagen deposition. IBI and IBI-BLM were surrounded by a collagen-rich fibrous capsule, e.g. Fig. 9 As indicated by the arrow in .

[0064] Fig.10 The results showed that at D7, the fibrous capsule of the IBI-BLM group was significantly thicker than that of the IBI group (p<0.05). Similarly, at D14 and D28, the IBI-BLM group showed thicker fibrous capsules than the IBI group (p<0.05), indicating increased collagen deposition around the embolic material. This enhanced fibrosis will help stabilize the intravascularly injected material, thereby effectively blocking abnormal blood vessels to achieve a lasting embolic effect.

[0065] IBI-BLM can completely and stably embolize the porcine renal artery

[0066] In order to evaluate whether blood flow was restored, the renal artery of pigs was selected for IBI-BLM embolization.

[0067] After embolization, DSA images showed no blood flow in the embolized renal artery, indicating that renal artery embolization was successfully achieved. After 14 days, no blood flow was restored.

[0068] The embolized kidney and the contralateral normal kidney were removed for histological evaluation. Fig.11 HE staining showed glomerular sclerosis, interstitial fibrosis and calcification, thickening of the renal arteriolar wall, stenosis of the lumen, and fibrinoid necrosis, indicating that the renal tissue structure was significantly damaged 14 days after embolization.

[0069] Establishment of bAVM model

[0070] The bAVM model was established by unilaterally performing anastomosis of the common carotid artery to the external jugular vein in pigs and ligating the external carotid artery below the arteriovenous fistula anastomosis.

[0071] IBI-BLM stabilizes embolized arteriovenous malformations and reduces recurrence in pigs

[0072] The microcatheter was advanced to a satisfactory embolization position. Then 1 ml of IBI or IBI-BLM was extracted with a syringe and injected multiple times with the syringe. Backflow of the nanogel around the microcatheter was observed during the injection, indicating successful embolization of the administration site. The contrast agent was preheated to 37 °C and reinjected into the microcatheter 10 minutes after administration. Compared with before embolization, angiography showed occlusion of the ascending pharyngeal artery and its branches, and no contrast agent passed through the artery, indicating that temporary embolization had been achieved. During the embolization process, vital signs such as blood pressure, respiratory rate, and heart rate were closely monitored, and no abnormalities were found.

[0073] The animals were housed in the laboratory according to the guidelines for animal experimentation, and some vital signs were recorded daily, such as body temperature, fluid intake and output, blood pressure, respiratory rate, and heart rate.

[0074] After 7, 14, and 28 days, the pigs were again angiographically evaluated for embolism. The pigs were sacrificed at the above time points and the rete mirabile (RM) was removed.

[0075] from Fig.12 , Fig.13 , Fig.14 It can be seen that 7 days after embolization, Masson staining showed that the IBI-BLM of RM was composed of amorphous material and a small amount of immature fibrous tissue proliferation. The thickness of the fibrous tissue of the vascular wall of the IBI-BLM injection was significantly greater than that of the IBI injection (p<0.05). 14 days after embolization, the thickness of the fibrous tissue of the vascular wall in the IBI-BLM group was significantly greater than that in the IBI group (p<0.05). The IBI-BLM group had more fibrous connective tissue than the IBI group. 28 days after embolization, the thickness of the fibrous tissue of the vascular wall in the IBI-BLM group was significantly greater than that in the IBI group (p<0.05). This enhanced fibrosis will help stabilize the intravascularly injected material to achieve durable embolization and prevent recanalization.

[0076] To evaluate any systemic side effects of IBI and IBI-BLM embolization, pig organs such as brain, liver, pancreas, lung, kidney, and heart were collected 28 days after embolization. Fig.15 HE staining showed that there was no lesion or inflammatory reaction in the above organs and tissues, indicating that the embolic material containing bleomycin of the present invention has high biological safety.

[0077] IBI-BLM can reduce recurrence through TGF-b / Smad 3 signaling pathway

[0078] Fig.16 , Fig.17It can be seen that on days 7, 14, and 28, the expressions of TGF-β, Smad 3, and p-Smad 3 in the IBI-BLM group were significantly increased compared with the IBI group (p<0.05).

[0079] Fig.18 , Fig.19 It can be seen that on days 7, 14, and 28, the expression levels of Collagen I, Collagen III, Collagen IV, Laminin a-2, and Fibronectin in the IBI-BLM group were significantly increased compared with the IBI group (p<0.05).

[0080] Therefore, the embolic material of the present invention can significantly promote fibrosis through the TGF-β / Smad 3 signaling pathway, thereby providing a long-term and stable embolic effect.

[0081] It can be understood that the above specific description of the present invention is only used to illustrate the present invention and is not limited to the technical solutions described in the embodiments of the present invention. Those skilled in the art should understand that the present invention can still be modified or replaced by equivalents to achieve the same technical effects; as long as the use requirements are met, they are within the protection scope of the present invention.

Claims

1. An embolic material containing bleomycin, characterized in that: The embolic material comprises a drug, a carrier and a developer; the drug is bleomycin, the carrier is pNIPAM-BMA nanogel, and the developer is iohexol.

2. The embolic material containing bleomycin according to claim 1, characterized in that: The concentration of bleomycin is 30 g / L, and the volume ratio of the pNIPAM-BMA nanogel to iohexol is 1:

1.

3. A method for preparing an embolic material containing bleomycin, characterized in that: The following steps are involved: First, pNIPAM-BMA nanogel was prepared by precipitation polymerization. Then, pNIPAM-BMA nanogel and iohexol were mixed in a volume ratio of 1:1 to form an IBI dispersion. Bleomycin was added to the IBI dispersion, wherein the concentration of the bleomycin was 30 g / L, and the bleomycin was fully mixed to obtain an embolic material containing bleomycin.

4. The method for preparing an embolic material containing bleomycin according to claim 3, characterized in that: The specific steps of preparing pNIPAM-BMA nanogel by the precipitation polymerization method are as follows: 1.13 g of N-isopropylacrylamide, 108 ul of butyl methacrylate, 3.2 mg of N,N'-methylenebisacrylamide and 17 mg of sodium dodecyl sulfate are added to 100 ml of ultrapure water, mixed, heated to 70° C., stirred, and nitrogen gas was introduced for 1 hour; then 27 mg of potassium persulfate was added to initiate polymerization, and the reaction was maintained at 70° C. for 4.5 hours to obtain an IB nanogel dispersion, which was dialyzed for 7 days to remove unreacted monomers and other small molecules to obtain a pNIPAM-BMA nanogel.

5. An application of an embolic material containing bleomycin, characterized in that: The bleomycin-containing embolic material according to claim 1 is used as an embolic agent for treating cerebral arteriovenous malformations.

Citation Information

Patent Citations

  • Temperature-sensitive nano-gel vascular embolic materials, preparation method and application thereof

    CN101690831A

  • Temperature-sensitive polymer, in-situ gelation temperature-sensitive liquid embolic material and preparation method thereof

    CN104130348A

  • Iodinated lipid emulsion vascular thrombosis material, preparation method and application thereof

    CN107261197A

  • Vascular occlusive agent, and preparation method and applications thereof

    CN113425886A

  • Temperature sensing nano gel system for blood vessel embolism material

    CN1923303A